{
    "id": 3347,
    "name": "osteosarcoma",
    "source": "DOID",
    "definition": "A bone sarcoma that is located_in bone that has_material_basis_in cells of mesenchymal origin. [url:http\\://en.wikipedia.org/wiki/Osteosarcoma, url:http\\://www.cancer.gov/dictionary?cdrid=45395]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        "183"
    ],
    "termId": "DOID:3347",
    "evidence": [
        {
            "id": 911,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TP53 R280M resulted in secondary resistance in an osteosarcoma cell line acquired during Nutlin-3 treatment (PMID: 21643018).",
            "molecularProfile": {
                "id": 1553,
                "profileName": "TP53 R280M"
            },
            "therapy": {
                "id": 1405,
                "therapyName": "Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 585,
                    "pubMedId": 21643018,
                    "title": "Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21643018"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 912,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TP53 I232S resulted in secondary resistance in an osteosarcoma cell line acquired during Nutlin-3 treatment (PMID: 21643018).",
            "molecularProfile": {
                "id": 1554,
                "profileName": "TP53 I232S"
            },
            "therapy": {
                "id": 1405,
                "therapyName": "Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 585,
                    "pubMedId": 21643018,
                    "title": "Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21643018"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 913,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TP53 E258Q resulted in secondary resistance in an osteosarcoma cell line acquired during Nutlin-3 treatment (PMID: 21643018).",
            "molecularProfile": {
                "id": 1552,
                "profileName": "TP53 E258Q"
            },
            "therapy": {
                "id": 1405,
                "therapyName": "Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 585,
                    "pubMedId": 21643018,
                    "title": "Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21643018"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 914,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, TP53 P177T resulted in secondary resistance in an osteosarcoma cell line acquired during Nutlin-3 treatment (PMID: 21643018).",
            "molecularProfile": {
                "id": 1484,
                "profileName": "TP53 P177T"
            },
            "therapy": {
                "id": 1405,
                "therapyName": "Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 585,
                    "pubMedId": 21643018,
                    "title": "Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21643018"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1098,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) inhibited tumor growth in osteosarcoma cell line xenograft models with wild-type TP53 and MDM2 amplification (PMID: 25567130, PMID: 24967612).",
            "molecularProfile": {
                "id": 2169,
                "profileName": "MDM2 amp TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 835,
                    "pubMedId": 24967612,
                    "title": "Discovery of a small molecule MDM2 inhibitor (AMG 232) for treating cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24967612"
                },
                {
                    "id": 2082,
                    "pubMedId": 25567130,
                    "title": "The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25567130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1788,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR405838 inhibited growth of TP53 wild-type, MDM2 amplified osteosarcoma in culture and resulted in tumor regression in cell line xenograft models (PMID: 25145672).",
            "molecularProfile": {
                "id": 2169,
                "profileName": "MDM2 amp TP53 wild-type"
            },
            "therapy": {
                "id": 2078,
                "therapyName": "SAR405838",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 1886,
                    "pubMedId": 25145672,
                    "title": "SAR405838: an optimized inhibitor of MDM2-p53 interaction that induces complete and durable tumor regression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25145672"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 3945,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BMS-754807 treatment resulted in significant tumor growth delay in 67% (4/6) of cell line xenograft models of osteosarcoma (PMID: 21298745).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 686,
                "therapyName": "BMS-754807",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4302,
                    "pubMedId": 21298745,
                    "title": "Initial testing (stage 1) of the IGF-1 receptor inhibitor BMS-754807 by the pediatric preclinical testing program.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21298745"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4122,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, a trial arm assessing Sprycel (dasatinib) in osteosarcoma patients (n=46) was suspended due to lack of drug activity (PMID: 26710211).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4408,
                    "pubMedId": 26710211,
                    "title": "SARC009: Phase 2 study of dasatinib in patients with previously treated, high-grade, advanced sarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26710211"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4321,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 I1680S in culture (PMID: 25104330).",
            "molecularProfile": {
                "id": 17691,
                "profileName": "NOTCH1 I1680S"
            },
            "therapy": {
                "id": 1084,
                "therapyName": "MRK-003",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3550,
                    "pubMedId": 25104330,
                    "title": "Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25104330"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4322,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 E1567K in culture (PMID: 25104330).",
            "molecularProfile": {
                "id": 17692,
                "profileName": "NOTCH1 E1567K"
            },
            "therapy": {
                "id": 1084,
                "therapyName": "MRK-003",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3550,
                    "pubMedId": 25104330,
                    "title": "Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25104330"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4323,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 A1552G in culture (PMID: 25104330).",
            "molecularProfile": {
                "id": 17693,
                "profileName": "NOTCH1 A1552G"
            },
            "therapy": {
                "id": 1084,
                "therapyName": "MRK-003",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3550,
                    "pubMedId": 25104330,
                    "title": "Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25104330"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4324,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 A1552V in culture (PMID: 25104330).",
            "molecularProfile": {
                "id": 17694,
                "profileName": "NOTCH1 A1552V"
            },
            "therapy": {
                "id": 1084,
                "therapyName": "MRK-003",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3550,
                    "pubMedId": 25104330,
                    "title": "Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25104330"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4325,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 A1570G in culture (PMID: 25104330).",
            "molecularProfile": {
                "id": 17695,
                "profileName": "NOTCH1 A1570G"
            },
            "therapy": {
                "id": 1084,
                "therapyName": "MRK-003",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3550,
                    "pubMedId": 25104330,
                    "title": "Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25104330"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4326,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 V1575A in culture (PMID: 25104330).",
            "molecularProfile": {
                "id": 17697,
                "profileName": "NOTCH1 V1575A"
            },
            "therapy": {
                "id": 1084,
                "therapyName": "MRK-003",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3550,
                    "pubMedId": 25104330,
                    "title": "Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25104330"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4327,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 V1599M in culture (PMID: 25104330).",
            "molecularProfile": {
                "id": 17698,
                "profileName": "NOTCH1 V1599M"
            },
            "therapy": {
                "id": 1084,
                "therapyName": "MRK-003",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3550,
                    "pubMedId": 25104330,
                    "title": "Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25104330"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4328,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 A1707T in culture (PMID: 25104330).",
            "molecularProfile": {
                "id": 6144,
                "profileName": "NOTCH1 A1707T"
            },
            "therapy": {
                "id": 1084,
                "therapyName": "MRK-003",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3550,
                    "pubMedId": 25104330,
                    "title": "Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25104330"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4329,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 R1683W in culture (PMID: 25104330).",
            "molecularProfile": {
                "id": 17699,
                "profileName": "NOTCH1 R1683W"
            },
            "therapy": {
                "id": 1084,
                "therapyName": "MRK-003",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3550,
                    "pubMedId": 25104330,
                    "title": "Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25104330"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4330,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, MRK-003 inhibited Notch1 signaling in a luciferase reporter assay in osteosarcoma cell lines overexpressing NOTCH1 V1676I in culture (PMID: 25104330).",
            "molecularProfile": {
                "id": 879,
                "profileName": "NOTCH1 V1676I"
            },
            "therapy": {
                "id": 1084,
                "therapyName": "MRK-003",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3550,
                    "pubMedId": 25104330,
                    "title": "Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25104330"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4359,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, R547 inhibited proliferation of osteosarcoma cell lines harboring mutant Tp53 and wild-type Rb1 (PMID: 17121911).",
            "molecularProfile": {
                "id": 17822,
                "profileName": "RB1 wild-type TP53 mut"
            },
            "therapy": {
                "id": 3497,
                "therapyName": "R547",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4503,
                    "pubMedId": 17121911,
                    "title": "In vitro and in vivo activity of R547: a potent and selective cyclin-dependent kinase inhibitor currently in phase I clinical trials.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/17121911"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4646,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CPUY201112 reduced viability and induced apoptosis in an osteosarcoma cell line with wild-type TP53 in culture, and had a limited effect on an osteosarcoma cell line lacking TP53 (PMID: 26743233).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 3589,
                "therapyName": "CPUY201112",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4657,
                    "pubMedId": 26743233,
                    "title": "CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26743233"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4647,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an osteosarcoma cell line lacking TP53 demonstrated a decreased response to CPUY201112 in culture, when compared to osteosarcoma cells with wild-type TP53 (PMID: 26743233).",
            "molecularProfile": {
                "id": 630,
                "profileName": "TP53 loss"
            },
            "therapy": {
                "id": 3589,
                "therapyName": "CPUY201112",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4657,
                    "pubMedId": 26743233,
                    "title": "CPUY201112, a novel synthetic small-molecule compound and inhibitor of heat shock protein Hsp90, induces p53-mediated apoptosis in MCF-7 cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26743233"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5043,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2830371 enhanced the sensitivity of Nutlin-3 treatment in TP53 wild-type osteosarcoma cancer cells harboring a PPM1D activating mutation, resulting in cell growth inhibition in culture (PMID: 26832796).",
            "molecularProfile": {
                "id": 20192,
                "profileName": "PPM1D act mut TP53 wild-type"
            },
            "therapy": {
                "id": 3736,
                "therapyName": "GSK2830371 + Nutlin-3",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4853,
                    "pubMedId": 26832796,
                    "title": "Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26832796"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5044,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GSK2830371 enhanced the sensitivity of RG7388 treatment in TP53 wild-type osteosarcoma cells harboring a PPM1D activating mutation, resulting in cell growth inhibition in culture (PMID: 26832796).",
            "molecularProfile": {
                "id": 20192,
                "profileName": "PPM1D act mut TP53 wild-type"
            },
            "therapy": {
                "id": 3737,
                "therapyName": "GSK2830371 + Idasanutlin",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4853,
                    "pubMedId": 26832796,
                    "title": "Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26832796"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5450,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LLL2 inhibited Stat3 signaling and cell proliferation in osteosarcoma cell lines in culture, and inhibited tumor growth in xenograft models (PMID: 21340507).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3592,
                "therapyName": "LLL12",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5064,
                    "pubMedId": 21340507,
                    "title": "Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21340507"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5456,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FLLL32 inhibited Stat3 signaling and cell proliferation in osteosarcoma cell lines in culture, and inhibited tumor growth in xenograft models (PMID: 21340507).",
            "molecularProfile": {
                "id": 20856,
                "profileName": "STAT3 positive"
            },
            "therapy": {
                "id": 3862,
                "therapyName": "FLLL32",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5064,
                    "pubMedId": 21340507,
                    "title": "Small molecules, LLL12 and FLLL32, inhibit STAT3 and exhibit potent growth suppressive activity in osteosarcoma cells and tumor growth in mice.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21340507"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6019,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, YW3-56 inhibited proliferation of a human osteosarcoma cell line in culture (PMID: 25612620).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4006,
                "therapyName": "YW3-56",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5233,
                    "pubMedId": 25612620,
                    "title": "ATF4 Gene Network Mediates Cellular Response to the Anticancer PAD Inhibitor YW3-56 in Triple-Negative Breast Cancer Cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25612620"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6089,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with VCN-01 resulted in decreased viability of osteosarcoma cell lines in culture (PMID: 26603261).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4038,
                "therapyName": "VCN-01",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5296,
                    "pubMedId": 26603261,
                    "title": "The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603261"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6090,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, VCN-01 decreased viability of a human RB1-mutant primary osteosarcoma cell line in culture, and inhibited tumor growth and decreased lung metastases in xenograft models (PMID: 26603261).",
            "molecularProfile": {
                "id": 22588,
                "profileName": "RB1 mutant"
            },
            "therapy": {
                "id": 4038,
                "therapyName": "VCN-01",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5296,
                    "pubMedId": 26603261,
                    "title": "The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26603261"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6112,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, osteosarcoma cells treated with VE-821 resulted in a synthetic lethal effect when combined with AZD7762, thereby demonstrating reduced cell survival in culture (PMID: 26748709).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4051,
                "therapyName": "AZD7762 + VE-821",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5316,
                    "pubMedId": 26748709,
                    "title": "Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26748709"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6120,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of AZD7762 and VE-821 enhanced the chemotherapeutic effects of Droxia (hydroxyurea) resulting in both increased nuclear fragmentation and apoptosis of osteosarcoma cells in culture (PMID: 26748709).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4050,
                "therapyName": "AZD7762 + Hydroxyurea + VE-821",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5316,
                    "pubMedId": 26748709,
                    "title": "Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26748709"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6299,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an osteosarcoma cell line xenograft model positive for Fap demonstrated sensitivity to RG7386, resulting in tumor growth inhibition (PMID: 27037412).",
            "molecularProfile": {
                "id": 23089,
                "profileName": "FAP positive"
            },
            "therapy": {
                "id": 4110,
                "therapyName": "RG7386",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5521,
                    "pubMedId": 27037412,
                    "title": "RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27037412"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6301,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an osteosarcoma patient derived xenograft (PDX) model positive for Fap demonstrated a greater sensitivity to the combination treatment of RG7386 and Adria (doxorubicin) when compared to either treatment alone, resulting in complete tumor remission (PMID: 27037412).",
            "molecularProfile": {
                "id": 23089,
                "profileName": "FAP positive"
            },
            "therapy": {
                "id": 4112,
                "therapyName": "Doxorubicin + RG7386",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5521,
                    "pubMedId": 27037412,
                    "title": "RG7386, a Novel Tetravalent FAP-DR5 Antibody, Effectively Triggers FAP-Dependent, Avidity-Driven DR5 Hyperclustering and Tumor Cell Apoptosis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27037412"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6346,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF4942847 inhibited proliferation and induced apoptosis in osteosarcoma cell lines over expressing Hsp90 in culture, and reduced tumor growth and metastasis in cell line xenograft models (PMID: 26712686).",
            "molecularProfile": {
                "id": 6899,
                "profileName": "HSP90AA1 over exp"
            },
            "therapy": {
                "id": 4120,
                "therapyName": "PF4942847",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5536,
                    "pubMedId": 26712686,
                    "title": "Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26712686"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6347,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PF4942847 and Zometa (zoledronic acid) worked synergistically to inhibit proliferation in osteosarcoma cell lines over expressing Hsp90 in culture, and to reduce tumor growth, metastasis and bone lesions in cell line xenograft models (PMID: 26712686).",
            "molecularProfile": {
                "id": 6899,
                "profileName": "HSP90AA1 over exp"
            },
            "therapy": {
                "id": 4121,
                "therapyName": "PF4942847 + Zoledronic acid",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 5536,
                    "pubMedId": 26712686,
                    "title": "Blocking HSP90 Addiction Inhibits Tumor Cell Proliferation, Metastasis Development, and Synergistically Acts with Zoledronic Acid to Delay Osteosarcoma Progression.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26712686"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6429,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, decreased Cblc expression through siRNA knockdown enhanced sensitivity to Lynparza (olaparib) in cultured osterosarcoma cell lines (PMID: 25883215).",
            "molecularProfile": {
                "id": 23413,
                "profileName": "CBLC dec exp"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5591,
                    "pubMedId": 25883215,
                    "title": "Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25883215"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7021,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SANT1 inhibited survival of osteosarcoma cell lines with reduced SMO mRNA level in culture (PMID: 26781311).",
            "molecularProfile": {
                "id": 24364,
                "profileName": "SMO dec exp"
            },
            "therapy": {
                "id": 3990,
                "therapyName": "SANT1",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 6046,
                    "pubMedId": 26781311,
                    "title": "Targeting hedgehog signaling pathway in pediatric tumors: in vitro evaluation of SMO and GLI inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26781311"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7261,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, GANT61 inhibited proliferation of osteosarcoma cells with GLI2 overexpression in culture (PMID: 24151134).",
            "molecularProfile": {
                "id": 5694,
                "profileName": "GLI2 over exp"
            },
            "therapy": {
                "id": 1786,
                "therapyName": "GANT61",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6265,
                    "pubMedId": 24151134,
                    "title": "Involvement and targeted intervention of dysregulated Hedgehog signaling in osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24151134"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7732,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SAR125844 inhibited survival of osteosarcoma cells harboring TPR-MET in culture (PMID: 25504634).",
            "molecularProfile": {
                "id": 25934,
                "profileName": "TPR - MET"
            },
            "therapy": {
                "id": 2159,
                "therapyName": "SAR125844",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2009,
                    "pubMedId": 25504634,
                    "title": "The selective intravenous inhibitor of the MET tyrosine kinase SAR125844 inhibits tumor growth in MET-amplified cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25504634"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8138,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of KRT-232 (AMG 232) and Adriamycin (doxorubicin) inhibited tumor growth and induced tumor regression in an MDM2-amplifed TP53 wild-type osteosarcoma cell line xenograft model, with increased efficacy over either agent alone (PMID: 25567130).",
            "molecularProfile": {
                "id": 2169,
                "profileName": "MDM2 amp TP53 wild-type"
            },
            "therapy": {
                "id": 4636,
                "therapyName": "Doxorubicin + KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2082,
                    "pubMedId": 25567130,
                    "title": "The MDM2 Inhibitor AMG 232 Demonstrates Robust Antitumor Efficacy and Potentiates the Activity of p53-Inducing Cytotoxic Agents.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25567130"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8254,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) treatment activated Tp53 signaling and resulted in growth inhibition of TP53 wild-type osteosarcoma cells in culture (PMID: 26162687).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 1452,
                "therapyName": "KRT-232",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6588,
                    "pubMedId": 26162687,
                    "title": "Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26162687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8260,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, KRT-232 (AMG 232) enhanced radiation-induced cytotoxicity in TP53 wild-type osteosarcoma cells in culture and in cell line xenograft models (PMID: 26162687).",
            "molecularProfile": {
                "id": 642,
                "profileName": "TP53 wild-type"
            },
            "therapy": {
                "id": 4671,
                "therapyName": "KRT-232 + Radiotherapy",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6588,
                    "pubMedId": 26162687,
                    "title": "Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26162687"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9314,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RO6839921 demonstrated anti-tumor activity in TP53 wild-type, MDM2 over-expressing osteosarcoma cell line xenograft models (Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A156).",
            "molecularProfile": {
                "id": 26380,
                "profileName": "MDM2 over exp TP53 wild-type"
            },
            "therapy": {
                "id": 2155,
                "therapyName": "RO6839921",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 7077,
                    "pubMedId": null,
                    "title": "Preclinical activity of MDM2 antagonist RO6839921, a pegylated prodrug for intravenous administration",
                    "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/A156.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 9860,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, WZ4003 inhibited MYPT1 phosphorylation and reduced invasive behavior and proliferation of an osteosarcoma cell line in culture (PMID: 24171924).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5271,
                "therapyName": "WZ4003",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7717,
                    "pubMedId": 24171924,
                    "title": "Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24171924"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9861,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, HTH-01-015 inhibited MYPT1 phosphorylation, invasive behavior, and proliferation of an osteosarcoma cell line in culture (PMID: 24171924).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5272,
                "therapyName": "HTH-01-015",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 7717,
                    "pubMedId": 24171924,
                    "title": "Characterization of WZ4003 and HTH-01-015 as selective inhibitors of the LKB1-tumour-suppressor-activated NUAK kinases.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24171924"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9966,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an osteosarcoma cell line with decreased expression of BAP1 via shRNA demonstrated sensitivity to treatment with Veliparib (ABT-888) in culture, resulting in decreased cell survival (PMID: 24894717).",
            "molecularProfile": {
                "id": 27219,
                "profileName": "BAP1 dec exp"
            },
            "therapy": {
                "id": 954,
                "therapyName": "Veliparib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6379,
                    "pubMedId": 24894717,
                    "title": "Germline mutations in BAP1 impair its function in DNA double-strand break repair.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24894717"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11034,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, V158411 inhibited Chk1 autophosphorylation and induced DNA damage and apoptosis in an osteosarcoma cell line in culture (PMID: 27829224).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5824,
                "therapyName": "V158411",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9030,
                    "pubMedId": 27829224,
                    "title": "Inhibition of Chk1 with the small molecule inhibitor V158411 induces DNA damage and cell death in an unperturbed S-phase.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27829224"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11091,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Keytruda (pembrolizumab) treatment resulted in partial response in 5% (1/22) of patients with osteosarcoma (J Clin Oncol 35, 2017 (suppl; abstr 11008)).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9070,
                    "pubMedId": null,
                    "title": "Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses.",
                    "url": "http://meetinglibrary.asco.org/record/145286/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11100,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, Keytruda (pembrolizumab) treatment resulted in 1 partial response in 2 patients with CD274 (PD-L1)-positive osteosarcoma (J Clin Oncol 35, 2017 (suppl; abstr 11008)).",
            "molecularProfile": {
                "id": 4746,
                "profileName": "CD274 positive"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9070,
                    "pubMedId": null,
                    "title": "Multicenter phase II study of pembrolizumab (P) in advanced soft tissue (STS) and bone sarcomas (BS): Final results of SARC028 and biomarker analyses.",
                    "url": "http://meetinglibrary.asco.org/record/145286/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11591,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of wild-type APOBEC3A in an osteosarcoma cell line enhanced sensitivity to VE-821 in culture (PMID: 28698210).",
            "molecularProfile": {
                "id": 28164,
                "profileName": "APOBEC3A pos APOBEC3A wild-type"
            },
            "therapy": {
                "id": 2877,
                "therapyName": "VE-821",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 9656,
                    "pubMedId": 28698210,
                    "title": "APOBEC3A and APOBEC3B Activities Render Cancer Cells Susceptible to ATR Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28698210"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11753,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Prexasertib (LY2606368) decreased proliferation of several pediatric tumor cell lines in culture, including osteosarcoma cell lines (PMID: 28270495).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1651,
                "therapyName": "Prexasertib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9764,
                    "pubMedId": 28270495,
                    "title": "The Checkpoint Kinase 1 Inhibitor Prexasertib Induces Regression of Preclinical Models of Human Neuroblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28270495"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 12558,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, the combination of Gemzar (gemcitabine) and Rapamune (sirolimus) resulted in a progression-free survival rate of 44% after 4 months in osteosarcoma patients, including a partial response in two patients and stable disease in fourteen patients (PMID: 29045512).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 6509,
                "therapyName": "Gemcitabine + Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10430,
                    "pubMedId": 29045512,
                    "title": "Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29045512"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13782,
            "approvalStatus": "Guideline",
            "evidenceType": "Risk Factor",
            "efficacyEvidence": "Germline mutations in TP53 result in Li-Fraumeni syndrome, which is associated with increased risk of developing osteosarcoma (NCCN.org).",
            "molecularProfile": {
                "id": 434,
                "profileName": "TP53 mutant"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15067,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Linsitinib (OSI-906) inhibited growth of osteosarcoma cells overexpressing Igf2bp3 in culture (PMID: 28193878).",
            "molecularProfile": {
                "id": 30727,
                "profileName": "IGF2BP3 over exp"
            },
            "therapy": {
                "id": 798,
                "therapyName": "Linsitinib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12604,
                    "pubMedId": 28193878,
                    "title": "THADA fusion is a mechanism of IGF2BP3 activation and IGF1R signaling in thyroid cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28193878"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16553,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Capmatinib (INC280) demonstrated safety and preliminary efficacy, resulted in stable disease as best overall response in a patients with osteosarcoma (PMID: 30724423).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1065,
                "therapyName": "Capmatinib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14616,
                    "pubMedId": 30724423,
                    "title": "Phase I dose-escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30724423"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16787,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, infusion of transgenic lymphocyte engineered to express NY-ESO-1-specific T-cell receptor together with NY-ESO-1 peptide-pulsed DC vaccine demonstrated initial antitumor activity at day 30 in a patient with CTAG1B (NY-ESO-1)-positive osteosarcoma, but the disease progressed at day 90 (PMID: 30573690; NCT02070406).",
            "molecularProfile": {
                "id": 15750,
                "profileName": "CTAG1B positive"
            },
            "therapy": {
                "id": 2696,
                "therapyName": "NY-ESO-1 peptide vaccine",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14911,
                    "pubMedId": 30573690,
                    "title": "A Pilot Trial of the Combination of Transgenic NY-ESO-1-reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30573690"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17249,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, NKTR-214 treatment inhibited growth of primary tumor, regrowth after amputation, and lung metastasis in disseminated and orthotopic mouse models of osteosarcoma (AACR Annual Meeting 2019, Abstract 3210).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5075,
                "therapyName": "NKTR-214",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15262,
                    "pubMedId": null,
                    "title": "A potential immunotherapeutic approach for the treatment of osteosarcoma",
                    "url": "https://www.abstractsonline.com/pp8/#!/6812/presentation/2527"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17678,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Keytruda (pembrolizumab) is included in guidelines for unresectable or metastatic MSI-high osteosarcoma patients who have progressed on prior therapy (NCCN.org).",
            "molecularProfile": {
                "id": 29714,
                "profileName": "MSI high"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 17739,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, osteosarcoma cells with Stag2 deficiency were resistant to treatment with Platinol (cisplatin) in culture, demonstrating decreased apoptotic activity and increased cell viability compared to wild-type Stag2 (PMID: 31157248).",
            "molecularProfile": {
                "id": 32784,
                "profileName": "STAG2 negative"
            },
            "therapy": {
                "id": 700,
                "therapyName": "Cisplatin",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 15757,
                    "pubMedId": 31157248,
                    "title": "STAG2 loss-of-function mutation induces PD-L1 expression in U2OS cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31157248"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 17961,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a pediatric patient with metastatic osteosarcoma demonstrated a partial response to treatment with Nexavar (sorafenib) for 51 months prior to recurrence, and analysis of the pre-progression tumor demonstrated presence of PDGFRA D846V, which was not present in the post-progression sample, suggesting that the PDGFRA variant may have conferred sensitivity to Nexavar (sorafenib) (PMID: 30318721).",
            "molecularProfile": {
                "id": 32920,
                "profileName": "PDGFRA D846V"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 15694,
                    "pubMedId": 30318721,
                    "title": "Prolonged response to sorafenib in a patient with refractory metastatic osteosarcoma and a somatic PDGFRA D846V mutation.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30318721"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18742,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DSP-0509 inhibited tumor growth and reduced metastatic lung nodules in a syngeneic mouse model of osteosarcoma (Cancer Res July 1 2018 (78) (13 Supplement) 4726).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8822,
                "therapyName": "DSP-0509",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16398,
                    "pubMedId": null,
                    "title": "Novel intravenous injectable TLR7 agonist, DSP-0509, synergistically enhanced antitumor immune responses in combination with anti-PD-1 antibody",
                    "url": "https://cancerres.aacrjournals.org/content/78/13_Supplement/4726"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20249,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, SP-2509 treatment inhibited viability of osteosarcoma cell lines in culture (PMID: 29997151).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 9301,
                "therapyName": "SP-2509",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17780,
                    "pubMedId": 29997151,
                    "title": "Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29997151"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20279,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, osteosarcoma cells expressing PALB2 P8L were sensitive to treatment with Lynparza (olaparib), demonstrating decreased cell growth in culture (PMID: 31586400).",
            "molecularProfile": {
                "id": 35014,
                "profileName": "PALB2 P8L"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17558,
                    "pubMedId": 31586400,
                    "title": "A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31586400"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20280,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, osteosarcoma cells expressing PALB2 L35P were sensitive to treatment with Lynparza (olaparib), demonstrating decreased cell growth in culture (PMID: 31586400).",
            "molecularProfile": {
                "id": 34476,
                "profileName": "PALB2 L35P"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17558,
                    "pubMedId": 31586400,
                    "title": "A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31586400"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20281,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, osteosarcoma cells expressing PALB2 R37H were sensitive to treatment with Lynparza (olaparib), demonstrating decreased cell growth in culture (PMID: 31586400).",
            "molecularProfile": {
                "id": 34480,
                "profileName": "PALB2 R37H"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17558,
                    "pubMedId": 31586400,
                    "title": "A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31586400"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20283,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, osteosarcoma cells expressing PALB2 L947S were sensitive to treatment with Lynparza (olaparib), demonstrating decreased cell growth in culture (PMID: 31586400).",
            "molecularProfile": {
                "id": 34486,
                "profileName": "PALB2 L947S"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17558,
                    "pubMedId": 31586400,
                    "title": "A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31586400"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20284,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, osteosarcoma cells expressing PALB2 L1119P were sensitive to treatment with Lynparza (olaparib), demonstrating decreased cell growth in culture (PMID: 31586400).",
            "molecularProfile": {
                "id": 34673,
                "profileName": "PALB2 L1119P"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17558,
                    "pubMedId": 31586400,
                    "title": "A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31586400"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20287,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, osteosarcoma cells expressing PALB2 T1030I were sensitive to treatment with Lynparza (olaparib), demonstrating decreased cell growth in culture (PMID: 31586400).",
            "molecularProfile": {
                "id": 12015,
                "profileName": "PALB2 T1030I"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17558,
                    "pubMedId": 31586400,
                    "title": "A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31586400"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20289,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, osteosarcoma cells expressing PALB2 W1140G were sensitive to treatment with Lynparza (olaparib), demonstrating decreased cell growth in culture (PMID: 31586400).",
            "molecularProfile": {
                "id": 34597,
                "profileName": "PALB2 W1140G"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17558,
                    "pubMedId": 31586400,
                    "title": "A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31586400"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20295,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, osteosarcoma cells expressing PALB2 L947F were sensitive to treatment with Lynparza (olaparib), demonstrating decreased cell growth in culture (PMID: 31586400).",
            "molecularProfile": {
                "id": 35046,
                "profileName": "PALB2 L947F"
            },
            "therapy": {
                "id": 837,
                "therapyName": "Olaparib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17558,
                    "pubMedId": 31586400,
                    "title": "A global functional analysis of missense mutations reveals two major hotspots in the PALB2 tumor suppressor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31586400"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20330,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, FK866 treatment inhibited viability of an osteosarcoma cell line harboring PPM1D P458fs in culture, and inhibited tumor growth in a cell line xenograft model (PMID: 31439867).",
            "molecularProfile": {
                "id": 35113,
                "profileName": "PPM1D R458fs"
            },
            "therapy": {
                "id": 5662,
                "therapyName": "FK866",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 17806,
                    "pubMedId": 31439867,
                    "title": "PPM1D mutations silence NAPRT gene\u00a0expression and confer NAMPT inhibitor sensitivity in glioma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31439867"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21281,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient derived xenograft (PDX) models with MYC amplification were sensitive to treatment with AT7519, demonstrating decreased tumor growth, apoptotic activity, and 30% tumor shrinkage in 3/8 models (PMID: 30266815).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 2727,
                "therapyName": "AT7519",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21282,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient derived xenograft (PDX) models of osteosarcoma with MYC amplification were sensitive to treatment with Dinaciclib (SCH 727965), demonstrating tumor growth inhibition (PMID: 30266815).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 719,
                "therapyName": "Dinaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21283,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient derived xenograft (PDX) models of osteosarcoma with MYC amplification were sensitive to treatment with Alvocidib (flavopiridol), demonstrating tumor growth inhibition (PMID: 30266815).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 628,
                "therapyName": "Alvocidib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21285,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient derived xenograft models of osteosarcoma with MYC amplification were sensitive to treatment with JQ1, demonstrating some tumor growth inhibition (PMID: 30266815).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 1574,
                "therapyName": "JQ1",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21286,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells from a patient derived xenograft (PDX) model of osteosarcoma with MYC amplification did not demonstrate increased apoptotic activity compared to control, but did show decreased cell viability when treated with I-BET151 in culture (PMID: 30266815).",
            "molecularProfile": {
                "id": 1426,
                "profileName": "MYC amp"
            },
            "therapy": {
                "id": 5953,
                "therapyName": "I-BET151",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21287,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient derived xenograft (PDX) models of osteosarcoma with CCNE1 amplification were sensitive to Dinaciclib (SCH 727965), demonstrating tumor growth inhibition (PMID: 30266815).",
            "molecularProfile": {
                "id": 1421,
                "profileName": "CCNE1 amp"
            },
            "therapy": {
                "id": 719,
                "therapyName": "Dinaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21288,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient derived xenograft (PDX) models of osteosarcoma with CCNE1 amplification were sensitive to Ibrance (palbociclib), demonstrating tumor growth inhibition (PMID: 30266815).",
            "molecularProfile": {
                "id": 1421,
                "profileName": "CCNE1 amp"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21289,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient derived xenograft (PDX) models of osteosarcoma with CCNE1 amplification were sensitive to AT7519, demonstrating tumor growth inhibition (PMID: 30266815).",
            "molecularProfile": {
                "id": 1421,
                "profileName": "CCNE1 amp"
            },
            "therapy": {
                "id": 2727,
                "therapyName": "AT7519",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21290,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient derived xenograft (PDX) models of osteosarcoma with CCNE1 amplification were sensitive to Barasertib (AZD1152), demonstrating tumor growth inhibition (PMID: 30266815).",
            "molecularProfile": {
                "id": 1421,
                "profileName": "CCNE1 amp"
            },
            "therapy": {
                "id": 662,
                "therapyName": "Barasertib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21291,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient derived xenograft (PDX) models of osteosarcoma with CDK4 amplification were sensitive to Ibrance (palbociclib), demonstrating tumor growth inhibition and increased apoptotic activity (PMID: 30266815).",
            "molecularProfile": {
                "id": 1422,
                "profileName": "CDK4 amp"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21292,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, patient derived xenograft models of osteosarcoma with AURKB amplification were sensitive to treatment with Barasertib (AZD1152), demonstrating decreased growth rate and increased apoptotic activity (PMID: 30266815).",
            "molecularProfile": {
                "id": 4609,
                "profileName": "AURKB amp"
            },
            "therapy": {
                "id": 662,
                "therapyName": "Barasertib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21293,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient derived xenograft (PDX) model of osteosarcoma with biallelic loss of PTEN was sensitive to treatment with MK2206, demonstrating reduced tumor growth and increased apoptotic activity (PMID: 30266815).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21294,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient derived xenograft (PDX) model of osteosarcoma with AKT1 amplification was sensitive to treatment with MK2206, demonstrating reduced tumor growth and increased apoptotic activity (PMID: 30266815).",
            "molecularProfile": {
                "id": 3110,
                "profileName": "AKT1 amp"
            },
            "therapy": {
                "id": 816,
                "therapyName": "MK2206",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21295,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient derived xenograft (PDX) model of osteosarcoma with biallelic PTEN loss was sensitive to treatment with Rapamune (sirolimus), demonstrating reduced tumor growth and increased apoptotic activity (PMID: 30266815).",
            "molecularProfile": {
                "id": 479,
                "profileName": "PTEN loss"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21296,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient derived xenograft model of osteosarcoma with VEGFA amplification was sensitive to treatment with Nexavar (sorafenib), demonstrating decreased tumor volume and cell proliferation and a tumor growth inhibition of 79% (PMID: 30266815)",
            "molecularProfile": {
                "id": 4727,
                "profileName": "VEGFA amp"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21297,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient derived xenograft (PDX) model of osteosarcoma with FOXM1 amplification was sensitive to treatment with Ibrance (palbociclib), demonstrating reduced tumor volume and tumor shrinkage (PMID: 30266815).",
            "molecularProfile": {
                "id": 36182,
                "profileName": "FOXM1 amp"
            },
            "therapy": {
                "id": 850,
                "therapyName": "Palbociclib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21298,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient derived xenograft (PDX) model of osteosarcoma with FOXM1 amplification was sensitive to treatment with AT7519, demonstrating tumor growth inhibition (PMID: 30266815).",
            "molecularProfile": {
                "id": 36182,
                "profileName": "FOXM1 amp"
            },
            "therapy": {
                "id": 2727,
                "therapyName": "AT7519",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 21299,
            "approvalStatus": "Preclinical - Pdx",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a patient derived xenograft (PDX) model of osteosarcoma with FOXM1 amplification demonstrated decreased inhibition of tumor growth when treated with Dinaciclib (SCH 727965) compared to treatment with Ibrance (palbociclib) and AT7519 (PMID: 30266815).",
            "molecularProfile": {
                "id": 36182,
                "profileName": "FOXM1 amp"
            },
            "therapy": {
                "id": 719,
                "therapyName": "Dinaciclib",
                "synonyms": null
            },
            "indication": {
                "id": 3347,
                "name": "osteosarcoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 18550,
                    "pubMedId": 30266815,
                    "title": "Genome-Informed Targeted Therapy for Osteosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30266815"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00902044",
            "title": "Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1166,
                    "therapyName": "Fludarabine",
                    "synonyms": null
                },
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 2940,
                    "therapyName": "HER2 sensitized T-cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01241162",
            "title": "Decitabine Followed by a Cancer Antigen Vaccine for Patients With Neuroblastoma and Sarcoma",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 650,
                    "therapyName": "Decitabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01331135",
            "title": "Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 917,
                    "therapyName": "Sirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01518413",
            "title": "Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1323,
                    "therapyName": "Irinotecan + Sorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01759303",
            "title": "Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung",
            "phase": "Phase II",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 848,
                    "therapyName": "Pazopanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01956669",
            "title": "Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 848,
                    "therapyName": "Pazopanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02013336",
            "title": "Phase 1 Study of MM-398 Plus Cyclophosphamide in Pediatric Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7579,
                    "therapyName": "Cyclophosphamide + MM-398",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02048371",
            "title": "A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02100891",
            "title": "Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                
            ]
        },
        {
            "nctId": "NCT02173093",
            "title": "Activated T Cells Armed With GD2 Bispecific Antibody in Children and Young Adults With Neuroblastoma and Osteosarcoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2058,
                    "therapyName": "Aldesleukin + GD2Bi-a ATC + Sargramostim",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02304458",
            "title": "Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas",
            "phase": "Phase Ib/II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02357810",
            "title": "Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1469,
                    "therapyName": "Pazopanib + Topotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02432274",
            "title": "Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1136,
                    "therapyName": "Etoposide",
                    "synonyms": null
                },
                {
                    "id": 792,
                    "therapyName": "Lenvatinib",
                    "synonyms": null
                },
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02446431",
            "title": "Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1148,
                    "therapyName": "Cyclophosphamide",
                    "synonyms": null
                },
                {
                    "id": 667,
                    "therapyName": "Bevacizumab",
                    "synonyms": null
                },
                {
                    "id": 936,
                    "therapyName": "Temsirolimus",
                    "synonyms": null
                },
                {
                    "id": 1076,
                    "therapyName": "Valproic acid",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02470091",
            "title": "Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1198,
                    "therapyName": "Denosumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02487979",
            "title": "Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 3597,
                    "therapyName": "Glembatumumab vedotin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02644460",
            "title": "Abemaciclib in Children With DIPG or Recurrent/Refractory Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 802,
                    "therapyName": "Abemaciclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02789228",
            "title": "Research Study Utilizing Expanded Multi-antigen Specific Lymphocytes for the Treatment of Solid Tumors (REST)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9602,
                    "therapyName": "MultiTAA-specific T cells",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02815995",
            "title": "Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02879162",
            "title": "Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2439,
                    "therapyName": "Durvalumab + Tremelimumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02982941",
            "title": "Enoblituzumab (MGA271) in Children With B7-H3-expressing Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 2863,
                    "therapyName": "MGA271",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03006848",
            "title": "A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 3144,
                    "therapyName": "Avelumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03139331",
            "title": "PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5635,
                    "therapyName": "Irinotecan + Pazopanib + Temozolomide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03190174",
            "title": "Nivolumab (Opdivo) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5931,
                    "therapyName": "Nab-Rapamycin + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03282344",
            "title": "A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5076,
                    "therapyName": "Nivolumab + NKTR-214",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03320330",
            "title": "VX15/2503 in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3738,
                    "therapyName": "VX15/2503",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03449108",
            "title": "Iovance Alliance: LN-145 Across Multiple Tumor Types",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6778,
                    "therapyName": "Cyclophosphamide + Fludarabine + Interleukin-12 + LN-145 + Mesna",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03458728",
            "title": "Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 995,
                    "therapyName": "Copanlisib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03628209",
            "title": "Nivolumab or Nivolumab and Azacitidine in Patients With Recurrent, Resectable Osteosarcoma",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 3196,
                    "therapyName": "Azacitidine + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03635632",
            "title": "C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9563,
                    "therapyName": "C7R-GD2.CART cells",
                    "synonyms": null
                },
                {
                    "id": 2291,
                    "therapyName": "Cyclophosphamide + Fludarabine",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03698994",
            "title": "Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 997,
                    "therapyName": "Ulixertinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03718091",
            "title": "M6620 (VX-970) in Selected Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2879,
                    "therapyName": "VX-970",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03900793",
            "title": "Losartan + Sunitinib in Treatment of Osteosarcoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8773,
                    "therapyName": "Losartan + Sunitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03960177",
            "title": "Glucarpidase After High-Dose Methotrexate in Patients With Osteosarcoma",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9621,
                    "therapyName": "Glucarpidase",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04040205",
            "title": "Abemaciclib for Treatment of Advanced Bone and Soft Tissue Sarcoma Identified as Having CDK Pathway Alteration",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 802,
                    "therapyName": "Abemaciclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04183062",
            "title": "BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 9032,
                    "therapyName": "BIO-11006 + Docetaxel + Gemcitabine",
                    "synonyms": null
                }
            ]
        }
    ]
}